Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Operating Leases (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Operating Leases for 3 consecutive years, with $186000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Operating Leases changed N/A year-over-year to $186000.0, compared with a TTM value of $186000.0 through Sep 2024, changed N/A, and an annual FY2023 reading of $342000.0, down 47.14% over the prior year.
  • Operating Leases was $186000.0 for Q3 2024 at Oramed Pharmaceuticals, down from $236000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.1 million in Q1 2022 and bottomed at $186000.0 in Q3 2024.
  • Average Operating Leases over 3 years is $505000.0, with a median of $342000.0 recorded in 2023.
  • Peak annual rise in Operating Leases hit 47.14% in 2023, while the deepest fall reached 47.14% in 2023.
  • Year by year, Operating Leases stood at $647000.0 in 2022, then tumbled by 47.14% to $342000.0 in 2023, then plummeted by 45.61% to $186000.0 in 2024.
  • Business Quant data shows Operating Leases for ORMP at $186000.0 in Q3 2024, $236000.0 in Q2 2024, and $272000.0 in Q1 2024.